



INSTITUT
JULES BORDET
INSTITUUT



VRIJE
UNIVERSITEIT
BRUSSEL

Brussels RadioTheranostic Platform (BRTP)

Zéna Wimana, PhD

Biomedical Scientist/ Coordinator
Nuclear Medicine/Radiopharmacy
Institut Jules Bordet

Tony Lahoutte, MD, PhD

Head of Nuclear Medicine UZ Brussel
Director ICMI VUB
CSO Camel-IDS

Oncology


Nuclear Medicine



European Alliance for
Personalised Medicine



INSTITUT
JULES BORDET
INSTITUUT





INSTITUT
JULES BORDET
INSTITUUT

**Major protagonist of the
Radiotheranostic approach**



VRIJE
UNIVERSITEIT
BRUSSEL

**Forefront of innovative
vectors based on single
domain fragments (sdAbs)**



INSTITUT
JULES BORDET
INSTITUUT

Brussels RadioTheranostic Platform = BRTP

Generation of
innovative
radiotheranostics

Radiobiology of
radiotheranostics

Design




Preclinical evaluation



Clinical Production



Clinical Evaluation




INSTITUT
JULES BORDET
INSTITUUT


Design



TARGET
VECTOR




Vector development



Vector development

2020



Vector development





Pharm Industry

R&D for Companion Imaging Diagnostics
Academic/Industrial Partnerships



Preclinical Imaging

Biodistribution, Target validation
Fundamental Research
Applied Research




Clinical Research

Diagnostic
Phase I / II / III clinical trials
Academic/Industrial Clinical Research

Clinical Practice



Introducing validated Radionuclide Therapeutics
in clinical practice



Design



TARGET
PROBE
RADIOLABELING



Alpha Lab

- **Radionuclides of interest for imaging:**

- ⇒ β^+ - decay: PET imaging

- ⇒ γ - decay: SPECT imaging

- **Radionuclides of interest for TRNT:**

- ⇒ β^- - decay



- ⇒ α - decay

- ⇒ Auger electron - decay


Classification by means of **linear energy transfer**

LET corresponds to the energy released over a certain distance.

For the same absorbed dose, high LET is more cytotoxic than low LET radiation.





Alpha Lab






Preclinical evaluation






Preclinical evaluation


in vitro




in vivo



ex vivo









Clinical Evaluation



Diagnostic
 ^{68}Ga -DOTATATE PET



Therapy
 ^{177}Lu -DOTATATE (SPECT)




“You see what you treat and treat what you see”





Clinical Evaluation



B RTP

Generation of innovative radiotheranostics

- ♦ R&D
- ♦ Vector development
- ♦ Alpha Lab
- ♦ Clinical production
- ♦ Translation to patient
- ♦ Bench to bedside

Radiobiology of radiotheranostics

- ♦ Radioresistance biomarkers
- ♦ Radiobiological dynamics
- ♦ Cancer cells, animal models, translationally on biological specimens

Network

- ♦ Scientist and Clinicians
- ♦ Exchanges and collaborations
- ♦ Academia and Industry

➔ Radiotheranostics to the forefront of oncology research

